In: Current Oncology Reports, 2021, vol. 23, no. 3, p. 10
Purpose of Review Richter syndrome (RS) is an uncommon but aggressive evolution of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). RS is an unmet clinical need in the field of CLL. Recent advances in understanding the biology of this condition provide the rationale for testing new therapeutic concepts in order to improve the outcome of patients developing RS, which is so far...
|
In: Acta Neuropathologica, 2015, vol. 129, no. 5, p. 679-693
|
In: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie, ///-
|
In: Supportive Care in Cancer, 2015, vol. 23, no. 2, p. 325-331
|
In: Scientific Reports, 2020, vol. 10, no. 1, p. 7078
Immunotherapies, such as checkpoint blockade of programmed cell death protein-1 (PD-1), have resulted in unprecedented improvements in survival for patients with lung cancer. Nonetheless, not all patients benefit equally and many issues remain unresolved, including the mechanisms of action and the possible effector function of immune cells from non-lymphoid lineages. The purpose of this...
|
In: Non-coding RNA, 2019, vol. 5, no. 3, p. 47
Diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) and follicular lymphoma (FL) are the most common B-cell lymphomas (BCL) in dogs. Recent investigations have demonstrated overlaps of these histotypes with the human counterparts, including clinical presentation, biologic behavior, tumor genetics, and treatment response. The molecular mechanisms that underlie canine BCL are...
|
In: Clinical and Translational Oncology, 2014, vol. 16, no. 1, p. 85-90
|
In: Journal of Neuro-Oncology, 2014, vol. 117, no. 1, p. 141-145
|
In: Current Treatment Options in Neurology, 2014, vol. 16, no. 1, p. 1-14
|
In: Oncogene, 2019, vol. 38, no. 15, p. 2814–2829
Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER−) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here, we provide experimental...
|